Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      First-in-human Trial: Cyxone begins Phase 1 trial with T20K for treatment of multiple sclerosis

      First-in-human Trial: Cyxone begins Phase 1 trial with T20K for treatment of multiple sclerosis

      Medical Dialogues Bureau15 July 2019 9:00 AM IST
      Cyxone's application to start a first-in-human, phase I, trial with their prophylactic drug candidate T20K targeting multiple sclerosis (MS) has been...
      Laurus Labs gets no USFDA observations for Vizag unit

      Laurus Labs gets no USFDA observations for Vizag unit

      Medical Dialogues Bureau14 July 2019 10:00 AM IST
      The maiden United States Food and Drug Administration (USFDA) audit for the unit was successfully completed without any observations and no Form 483...
      Eton Pharma fails to win USFDA nod for conjunctivitis treatment

      Eton Pharma fails to win USFDA nod for conjunctivitis treatment

      Medical Dialogues Bureau14 July 2019 9:30 AM IST
      The company sold the U.S. rights to its EM-100 eye drop for treating itching associated with allergic conjunctivitis to Bausch Health Companies Inc in...
      Milestone payment from Sanofi to Schrödinger for providing molecular simulation, computational design expertise

      Milestone payment from Sanofi to Schrödinger for providing molecular simulation, computational design expertise

      Medical Dialogues Bureau14 July 2019 9:16 AM IST
      Under the terms of the collaboration, Schrödinger provides advanced molecular simulation and computational design expertise to Sanofi across multiple...
      USFDA clears Centerline flagship product Intra-Operative Positioning System

      USFDA clears Centerline flagship product Intra-Operative Positioning System

      Medical Dialogues Bureau14 July 2019 9:15 AM IST
      CLEVELAND: Centerline Biomedical, Inc. (Centerline) has announced that the company has received 510(k) clearance from the United States Food and Drug...
      Biomarck Pharma starts phase 2 trial of BIO-11006 for Non-Small Cell Lung Cancer

      Biomarck Pharma starts phase 2 trial of BIO-11006 for Non-Small Cell Lung Cancer

      Medical Dialogues Bureau14 July 2019 9:00 AM IST
      Durham: Biomarck Pharmaceuticals, Ltd recently announced that a Phase 2 clinical study in advanced NSCLC has commenced. This study at 10 sites in...
      Now criminal probe against JnJ for denying presence of carcinogens in Baby Powder: Report

      Now criminal probe against JnJ for denying presence of carcinogens in Baby Powder: Report

      Medical Dialogues Bureau13 July 2019 1:15 PM IST
      The criminal probe, which hasn’t been reported previously, coincides with a regulatory investigation and civil claims by thousands of cancer patients...
      Biocon Chief Kiran Mazumdar Shaw, husband donate over Rs 51 crore to University of Glasgow

      Biocon Chief Kiran Mazumdar Shaw, husband donate over Rs 51 crore to University of Glasgow

      Medical Dialogues Bureau13 July 2019 12:55 PM IST
      A further donation of USD 2.5 million will go towards creating a new Professorial Chair to be named the Mazumdar-Shaw Chair of Precision Oncology....
      Sandoz launches SYMJEPI Injection in US to help treat allergic reactions

      Sandoz launches SYMJEPI Injection in US to help treat allergic reactions

      Medical Dialogues Bureau13 July 2019 9:32 AM IST
      SYMJEPI is a small, single-dose, pre-filled syringe and device combination as an alternative to epinephrine auto-injectors for the emergency treatment...
      Valeo Pharma launches Onstryv for treating Parkinsons disease in Canada

      Valeo Pharma launches Onstryv for treating Parkinsons disease in Canada

      Medical Dialogues Bureau13 July 2019 9:30 AM IST
      Onstryv is a prescription medication that can now be obtained at pharmacies across Canada and is available in 50mg and 100mg tablets. Valeo Pharma’s...
      Reckitt Benckiser pays USD 1.4 billion to settle opioid treatment spat

      Reckitt Benckiser pays USD 1.4 billion to settle opioid treatment spat

      Medical Dialogues Bureau13 July 2019 9:00 AM IST
      London: British consumer health giant Reckitt Benckiser announced Thursday it will pay up to $1.4 billion (1.2 billion euros) to settle a dispute...
      NPPA regulatory measures primarily triggered tough days for hospital sector, says Icra

      NPPA regulatory measures primarily triggered tough days for hospital sector, says Icra

      Medical Dialogues Bureau12 July 2019 6:23 PM IST
      The tough days were triggered primarily on account of several regulatory measures, including the cap on prices of stents and knee implants by the...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok